AT9283 is a multi-targeted inhibitor with IC50s of 4, 1.2, 1.1 and approximate 3 nM for Bcr-Abl (T315I), JAK2 and JAK3, Aurora A and Aurora B, respectively.

Gandotinib (LY2784544) 是一种强效的 JAK2 抑制剂，其 IC50 为 3 nM。Gandotinib (LY2784544) 还抑制 FLT3、FLT4、FGFR2、TYK2 和 TRKB，其 IC50 值分别为 4 nM、25 nM、32 nM、44 nM 和 95 nM。

Baricitinib（LY3009104；INCB028050）是一种选择性、口服可用的JAK1和JAK2抑制剂，对它们的IC50分别为5.9 nM和5.7 nM。

Pacritinib (SB1518) 是一种强效抑制野生型 JAK2 (IC50 = 23 nM) 和 JAK2V617F 突变体 (IC50 = 19 nM) 的抑制剂，同时也抑制 FLT3 (IC50 = 22 nM) 及其突变体 FLT3D835Y (IC50 = 6 nM)。

S-Ruxolitinib is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM, > 130-fold selectivity for JAK1/2 versus JAK3.

Oclacitinib Fumarate is a potent JAK inhibitor with IC50 value ranging in 10-99 nM for JAK family members, most potent against JAK1 with IC50 value of 10 nM.

Decernotinib is a selective JAK3 inhibitor with Ki value of 2.5nM, with >4-fold selectivity over JAK1, JAK2, and TYK2 with Ki values of 11nM, 13nM and 13nM, respectively.

Cerdulatinib (PRT062070) 是一种有效且选择性的 Tyk2 抑制剂，IC50 为 0.5 nM。它是 JAK 和 SYK 的双重抑制剂，对 JAK1、JAK2、JAK3 和 SYK 的 IC50 值分别为 12、6、8 和 32 nM。

Filgotinib is a selective JAK1/2 inhibitor with IC50 values of 10/28nM, with less potency against JAK3 and TYK2 with IC50 values of 810 nM and 116 nM, respectively.

BMS-911543 is a selective ATP-competitive JAK2 inhibitor with IC50 value of 1.1 nM, with much less potency against JAK1, JAK3 and TYK2 with IC50 values of 360nM, 75 nM and 66nM.

NVP-BSK805 2HCl is a potent and selective ATP-competitive JAK2 inhibitor with IC50 of 0.5 nM and > 20-fold selectivity towards JAK1, JAK3 and TYK2.